LANTUS

Compare LANTUS  to:
Compare
Compare

Generic Name for LANTUS

Insulin glargine (recombinant) 100 IU/mL; inj; contains m-cresol.

Legal Classification:

Rx

Manufacturer of LANTUS

Sanofi-aventis

Indications for LANTUS

Type 1 diabetes (in adults and children) and type 2 diabetes (in adults) when basal (long-acting) insulin is needed.

Adults and Children:

Give once daily at same time each day; SC inj only. Onset 1.1 hrs, no pronounced peak, duration 24 hrs or longer. <6yrs: not recommended. ≥6yrs: individualize; monitor and adjust as needed. Switching from once-daily NPH or ultralente insulin: initial dose should be the same on a unit-for-unit basis. Switching from twice-daily NPH: reduce initial insulin glargine dose by 20% from previous total NPH dose. Insulin-naive, type 2 diabetics on oral antidiabetic: initially 10 IU; range 2–100 IU.

Warnings/Precautions for LANTUS

Instruct patients on diet, exercise, blood or urine testing, proper administration of insulin, change in species of origin, type or purity of insulin, and management of hypoglycemia. Dosage increase may be required during infection, illness, stress, trauma, and pregnancy. Dosage decrease may be needed with renal or hepatic dysfunction. Pregnancy (Cat.C). Nursing mothers.

Interactions for LANTUS

Do not mix or dilute with other insulins. Potentiated by salicylates, MAOIs, alcohol, sulfa drugs, some ACE inhibitors, drugs that inhibit pancreatic function (eg, octreotide). Antagonized by corticosteroids, isoniazid, niacin, thiazides, phenothiazines, sympathomimetics. Variable effects with β-blockers, clonidine, lithium salts, alcohol.

Adverse Reactions for LANTUS

Pain, other inj site reactions, pruritus, rash, hypoglycemia, hypokalemia, lipodystrophy, edema.

How is LANTUS supplied?

Vials (10mL)—1
Cartridges (3mL)—5 (for OptiClik)
Lantus SoloStar pen (3mL)—5 (prefilled, disposable inj device)

Related Disease:

Diabetes mellitus~hyperglycemic agents

Related Resources

Finesse insulin patch-pen approved for use with Novolog

July 26, 2010

The FDA has approved Finesse, an insulin patch-pen from Calibra Medical, for up to three-day use with Novolog (insulin aspart, from Novo Nordisk).

Phase 2b study of ARC-4558 for painful diabetic neuropathy (PDN)

July 20, 2010

Arcion Therapeutics announced positive results from a Phase 2b, double-blind, randomized, placebo-controlled clinical trial of ARC-4558 (clonidine HCl 0.1% topical gel) in patients with painful diabetic neuropathy (PDN).

FDA conducts safety review of cancer risk with angiotensin receptor blockers (ARBs)

July 15, 2010

A recently published meta-analysis combining cancer-related findings from several clinical trials is suggesting that angiotensin receptor blockers (ARBs) may be associated with a small increased risk of cancer.

Phase 2b study of INT131 for the treatment of type 2 diabetes

July 01, 2010

InteKrin Therapeutics announced results from its Phase 2b study of INT131 for the treatment of type 2 diabetes.

Phase 1 and 2 studies of antisense therapy for type 2 diabetes

July 01, 2010

Isis Pharmaceuticals announced the presentation of data from its clinical trials of ISIS 113715 and ISIS-GCGRRx for the treatment of diabetes.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization.

Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions